Currently, Transmedics Group Inc [TMDX] is trading at $139.40, up 0.25%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TMDX shares have gain 12.47% over the last week, with a monthly amount glided 49.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on December 17, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $75 from $116. Previously, Needham downgraded its rating to Hold on November 22, 2024. On October 29, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $125 on the stock. Needham reiterated its Buy rating and decreased its price target to $109 on October 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $200 as its price target on September 24, 2024. Needham started tracking with a Buy rating for this stock on August 21, 2024, and assigned it a price target of $208. In a note dated June 06, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $161 on this stock.
This stock has fluctuated between a low of $55.00 and a high of $177.37 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $105 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $139.40 at the most recent close of the market. An investor can expect a potential drop of -24.68% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Trailing Twelve Months sales for Transmedics Group Inc [NASDAQ:TMDX] were 488.23M which represents 48.21% growth. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.1%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.22 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 136.78 points at the first support level, and at 134.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 141.35, and for the 2nd resistance point, it is at 143.30.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Transmedics Group Inc [NASDAQ:TMDX] is 9.10. Also, the Quick Ratio is 8.32, while the Cash Ratio stands at 5.58. Considering the valuation of this stock, the price to sales ratio is 9.66, the price to book ratio is 17.71 and price to earnings (TTM) ratio is 102.45.
Transactions by insiders
Recent insider trading involved Basile Edward M, Director, that happened on May 27 ’25 when 5000.0 shares were sold. Director, EDWARD BASILE completed a deal on May 27 ’25 to buy 5000.0 shares. Meanwhile, Director Weill David sold 732.0 shares on May 23 ’25.
